rss
Arch Dis Child 2003;88:715-718 doi:10.1136/adc.88.8.715
  • Acute paediatrics

Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis

  1. N M Byrne1,
  2. P M Keavey2,
  3. J D Perry3,
  4. F K Gould3,
  5. D A Spencer1
  1. 1Regional Paediatric Cystic Fibrosis Unit, Newcastle upon Tyne Hospitals NHS Trust, UK
  2. 2Regional Medical Physics Department, Newcastle upon Tyne Hospitals NHS Trust
  3. 3Microbiology Department, Newcastle upon Tyne Hospitals NHS Trust
  1. Correspondence to:
    Mrs N Byrne, Rehabilitation Department, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK;
    nuala.byrne{at}nuth.northy.nhs.uk
  • Accepted 4 November 2002

Abstract

Aim: To examine the effectiveness of delivery of nebulised colistin by the HaloLite nebuliser compared to the Pari LC Plus in patients with cystic fibrosis.

Methods: Randomised crossover trial of 15 patients aged >6 years. Inhalation of one mega unit of colistin in 3 ml diluent, labelled with technetium-99m DTPA, was used to assess lung deposition. The Pari was nebulised to dryness and one button press of the HaloLite was completed. Following a seven day washout period, patients inhaled colistin twice daily for seven days through the first device. Sputum specimens were analysed for colistin levels and pseudomonas load. This procedure was repeated with the alternative device.

Results: Lung uptake of radiolabelled colistin was significantly higher with the Pari. However, lung uptake calculated as a percentage of the amount of drug used was significantly higher for the HaloLite. Time to nebulise was significantly shorter with the HaloLite. Sputum levels of colistin were higher following use of the Pari; this was close to significance.

Conclusion: The manufacturer’s recommended dosages for nebulising antibiotics with a HaloLite result in a lower delivery than patients receive when using a Pari nebuliser. The concept of adaptive aerosol delivery has several theoretical advantages but the recommended doses for the HaloLite need to be modified in order to improve effectiveness.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content


    Free trial
    Individuals may register for a free 30 day online trial to all content.

    Free archive
    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.